These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37650859)

  • 1. Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.
    Lissing M; Wester A; Vassiliou D; Floderus Y; Harper P; Sardh E; Wahlin S
    J Inherit Metab Dis; 2023 Nov; 46(6):1186-1194. PubMed ID: 37650859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
    Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
    Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria.
    Marsden JT; Rees DC
    J Clin Pathol; 2014 Jan; 67(1):60-5. PubMed ID: 23908454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria.
    Aarsand AK; Petersen PH; Sandberg S
    Clin Chem; 2006 Apr; 52(4):650-6. PubMed ID: 16595824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of glycerol and dextrose on porphyrin precursor excretion in acute intermittent porphyria.
    Bonkowsky HL; Magnussen CR; Collins AR; Doherty JM; Hess RA; Tschudy DP
    Metabolism; 1976 Apr; 25(4):405-14. PubMed ID: 1263834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.
    Lissing M; Vassiliou D; Floderus Y; Harper P; Bottai M; Kotopouli M; Hagström H; Sardh E; Wahlin S
    J Intern Med; 2022 Jun; 291(6):824-836. PubMed ID: 35112415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes.
    Sardh E; Andersson DE; Henrichson A; Harper P
    Cell Mol Biol (Noisy-le-grand); 2009 Feb; 55(1):66-71. PubMed ID: 19268004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute intermittent porphyria in childhood: a population-based study.
    Hultdin J; Schmauch A; Wikberg A; Dahlquist G; Andersson C
    Acta Paediatr; 2003 May; 92(5):562-8. PubMed ID: 12839285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
    Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
    Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.
    Zhang J; Yasuda M; Desnick RJ; Balwani M; Bishop D; Yu C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Aug; 879(24):2389-96. PubMed ID: 21783436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion of porphyrins and porphyrin precursors during neuromuscular paralysis produced by dithiobiuret.
    Atchison WD; Peterson RE
    Exp Neurol; 1984 Jul; 85(1):63-8. PubMed ID: 6428932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.